Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Financing Activities (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Cash from Financing Activities for 10 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 219.85% year-over-year to $2.5 million, compared with a TTM value of $12.1 million through Dec 2025, down 85.31%, and an annual FY2025 reading of $12.1 million, down 85.31% over the prior year.
  • Cash from Financing Activities was $2.5 million for Q4 2025 at Zevra Therapeutics, down from $6.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $74.3 million in Q1 2021 and bottomed at -$4.7 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $12.2 million, with a median of $1.8 million recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 7183.33% in 2021, while the deepest fall reached 6139.13% in 2021.
  • Year by year, Cash from Financing Activities stood at -$2.9 million in 2021, then surged by 88.68% to -$325000.0 in 2022, then soared by 1639.69% to $5.0 million in 2023, then tumbled by 84.09% to $796000.0 in 2024, then surged by 219.85% to $2.5 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ZVRA at $2.5 million in Q4 2025, $6.5 million in Q3 2025, and $1.4 million in Q2 2025.